128 related articles for article (PubMed ID: 38691847)
1. Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor.
Moure CJ; Vara B; Cheng MM; Sondey C; Muise E; Park E; Vela Ramirez JE; Su D; D'Souza S; Yan Q; Yeung CS; Zhang M; Mansueto MS; Linn D; Buchanan M; Foti R; DiMauro E; Long B; Simov V; Barry ER
Mol Cancer Ther; 2024 May; ():OF1-OF14. PubMed ID: 38691847
[TBL] [Abstract][Full Text] [Related]
2. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
[TBL] [Abstract][Full Text] [Related]
3. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
[TBL] [Abstract][Full Text] [Related]
4. The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.
Kandasamy S; Adhikary G; Rorke EA; Friedberg JS; Mickle MB; Alexander HR; Eckert RL
Mol Cancer Res; 2020 Mar; 18(3):343-351. PubMed ID: 31732616
[TBL] [Abstract][Full Text] [Related]
5. Chloroacetamide fragment library screening identifies new scaffolds for covalent inhibition of the TEAD·YAP1 interaction.
Bum-Erdene K; Ghozayel MK; Zhang MJ; Gonzalez-Gutierrez G; Meroueh SO
RSC Med Chem; 2023 Sep; 14(9):1803-1816. PubMed ID: 37731696
[TBL] [Abstract][Full Text] [Related]
6. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
7. YAP1 is essential for malignant mesothelioma tumor maintenance.
Calvet L; Dos-Santos O; Spanakis E; Jean-Baptiste V; Le Bail JC; Buzy A; Paul P; Henry C; Valence S; Dib C; Pollard J; Sidhu S; Moll J; Debussche L; Valtingojer I
BMC Cancer; 2022 Jun; 22(1):639. PubMed ID: 35689194
[TBL] [Abstract][Full Text] [Related]
8. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
Ota M; Sasaki H
Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic Hedgehog-Smoothened Signaling Depends on YAP1‒TAZ/TEAD Transcription to Restrain Differentiation in Basal Cell Carcinoma.
Yuan Y; Salinas Parra N; Chen Q; Iglesias-Bartolome R
J Invest Dermatol; 2022 Jan; 142(1):65-76.e7. PubMed ID: 34293352
[TBL] [Abstract][Full Text] [Related]
10. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
[TBL] [Abstract][Full Text] [Related]
11. Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine.
Barry ER; Simov V; Valtingojer I; Venier O
Cells; 2021 Oct; 10(10):. PubMed ID: 34685695
[TBL] [Abstract][Full Text] [Related]
12. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity.
Yuan Y; Park J; Feng A; Awasthi P; Wang Z; Chen Q; Iglesias-Bartolome R
Nat Commun; 2020 Mar; 11(1):1472. PubMed ID: 32193376
[TBL] [Abstract][Full Text] [Related]
13. Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation.
Adhikary G; Shrestha S; Naselsky W; Newland JJ; Chen X; Xu W; Emadi A; Friedberg JS; Eckert RL
Mol Carcinog; 2023 Apr; 62(4):438-449. PubMed ID: 36562471
[TBL] [Abstract][Full Text] [Related]
14. The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.
González-Alonso P; Zazo S; Martín-Aparicio E; Luque M; Chamizo C; Sanz-Álvarez M; Minguez P; Gómez-López G; Cristóbal I; Caramés C; García-Foncillas J; Eroles P; Lluch A; Arpí O; Rovira A; Albanell J; Piersma SR; Jimenez CR; Madoz-Gúrpide J; Rojo F
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365528
[TBL] [Abstract][Full Text] [Related]
15. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.
Graham K; Lienau P; Bader B; Prechtl S; Naujoks J; Lesche R; Weiske J; Kuehnlenz J; Brzezinka K; Potze L; Zanconato F; Nicke B; Montebaur A; Bone W; Golfier S; Kaulfuss S; Kopitz C; Pilari S; Steuber H; Hayat S; Kamburov A; Steffen A; Schlicker A; Buchgraber P; Braeuer N; Font NA; Heinrich T; Kuhnke L; Nowak-Reppel K; Stresemann C; Steigemann P; Walter AO; Blotta S; Ocker M; Lakner A; von Nussbaum F; Mumberg D; Eis K; Piccolo S; Lange M
Cell Chem Biol; 2024 Mar; ():. PubMed ID: 38537632
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells.
Fisher ML; Grun D; Adhikary G; Xu W; Eckert RL
Oncotarget; 2017 Dec; 8(66):110257-110272. PubMed ID: 29299145
[TBL] [Abstract][Full Text] [Related]
17. Loss of
Goto H; Nishio M; To Y; Oishi T; Miyachi Y; Maehama T; Nishina H; Akiyama H; Mak TW; Makii Y; Saito T; Yasoda A; Tsumaki N; Suzuki A
Development; 2018 Mar; 145(6):. PubMed ID: 29511023
[TBL] [Abstract][Full Text] [Related]
18. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
Ko S; Kim M; Molina L; Sirica AE; Monga SP
Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
[TBL] [Abstract][Full Text] [Related]
19. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.
Fan M; Lu W; Che J; Kwiatkowski NP; Gao Y; Seo HS; Ficarro SB; Gokhale PC; Liu Y; Geffken EA; Lakhani J; Song K; Kuljanin M; Ji W; Jiang J; He Z; Tse J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Mancias JD; Marto JA; Dhe-Paganon S; Zhang T; Gray NS
Elife; 2022 Oct; 11():. PubMed ID: 36300789
[TBL] [Abstract][Full Text] [Related]
20. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
